bristol-myers squibb news

Bristol Myers Squibb Co. stock rises Monday, still underperforms market

Bristol Myers Squibb Co. closed $4.40 below its 52-week high ($61.08), which the company achieved on November 11th.

Why Did Bristol-Myers Squibb Co (BMY) Stock See 4.37% Surge in the Last 90 Days?

Bristol-Myers Squibb Co (BMY) stock saw a decline, ending the day at $56.57 which represents a decrease of $-0.22 or -0.39% from the prior close of $56.79. The stock opened at $56.34 and touched a low of $56.

Benzinga.com · 6d

Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture?

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Bristol-Myers Squibb's whale activity within a strike price range from $43.0 to $75.0 in the last 30 days.

YAHOO!Finance · 3d

Bristol Myers Squibb (BMY) Stock Declines While Market Improves: Some Information for Investors

Bristol Myers Squibb (BMY) closed the most recent trading day at $56.59, moving -0.35% from the previous trading session.

MarketWatch · 3d

Bristol Myers Squibb Co. stock rises Friday, still underperforms market

The stock's fall snapped a two-day winning streak.

Business Insider · 4d

Bristol Myers Squibb call volume above normal and directionally bullish

Bullish option flow detected in Bristol Myers Squibb with 203,938 calls trading, 22x expected, and implied vol increasing over 5 points to 22.90%. Jan-25 52.5 calls and Jan-25 50

Bristol-Myers Squibb (NYSE:BMY) Has A Pretty Healthy Balance Sheet

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company is, we ...

19mon MSN

Should Bristol-Myers Squibb Company (NYSE:BMY) Be In Your Early Retirement Portfolio?

We recently compiled a list of the Early Retirement Portfolio: 10 Stocks to Live Off Dividends. In this article, we are going ...

12hon MSN

Bristol Myers to report Q4 IPRD/licensing expense of $18M

Bristol Myers Squibb (NYSE:BMY) said it expects to report a Q4 net expense of $18M related to acquired IPRD and licensing ...

FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo

The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...

Pharmaceutical Technology1d

Zolacabtagene autoleucel by Bristol-Myers Squibb for Marginal Zone B-cell Lymphoma: Likelihood of Approval

Zolacabtagene autoleucel is under clinical development by Bristol-Myers Squibb and currently in Phase I for Marginal Zone B-cell Lymphoma.

Bristol-Myers Squibb Stock: Clearly Undervalued, Excellent 2H24 Culminates In Opdivo 'Subcu' Approval

Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why ...

Baylor College of Medicine1d

Baylor College of Medicine

Texas Children’s Global HOPE and Baylor College of Medicine Global Health, with support from the Bristol Myers Squibb Foundation, an independent charitable organization, announced the next front in ...

Pharmaceutical Technology1d

BMS-986484 by Bristol-Myers Squibb for Non-Small Cell Lung Cancer: Likelihood of Approval

BMS-986484 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Non-Small Cell Lung Cancer.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results